Economic effect of cholinesterase inhibitor therapy: Implications for managed care

Managed Care Interface

Volumn 17, Issue 8, 2004, Pages 44-49

  Sano, Mary ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CAREGIVER; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; MANAGED CARE; REVIEW; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CHRONIC DISEASE; COMORBIDITY; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HOME NURSING; HUMANS; MANAGED CARE PROGRAMS; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 4444334993     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Kirschstein R. Disease-specific estimates of direct and indirect costs of illness and NIH support. National Institutes of Health, June 2002 (www.od.nih.gov/osp/ospp/ecostudies/COIreportweb.htm).
2. Evans DA: Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990;68:267-289.
3. Katzman R, Fox PJ. The world-wide impact of dementia: Projections of prevalence and costs, in Mayeux R, Christen Y (eds): Epidemiology of Alzheimer's Disease: From Gene to Prevention. Heidelberg, Springer-Verlag, 1999;1-17.
4. Torian L, Davidson E, Fulop G, et al: The effect of dementia on acute care in a geriatric medical unit. Int Psychogeriatr 1992;4:231-239.
5. Hill JW, Futterman R, Duttagupta S, et al: Alzheimer's disease and related dementias increase costs of comorbidities in managed-Medicare. Neurology 2002;58:62-70.
6. Gutterman EM, Markowitz JS, Lewis B, et al: Cost of Alzheimer's disease wind related dementia in managed-Medicare. J Am Geriatr Soc 1999:47:1065-1071.
7. Hay J, Ernst R: The economic cost of Alzheimer's disease. Am J Public Health 1987;77:1169-1175.
8. Linkins KW. Lloyd JR: Treatment of Alzheimer's disease patients in a managed care organization: A descriptive cost study of costs and utilization. Drug Benefit Trends 2000;12:6-12.
9. Menzin J. Lang K, Friedman M, et al: The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995. Am J Geriatr Psychiatry 1999;7:300-308.
10. Fishman P, Von Korff M, Lozano M. et al: Chronic care costs in managed care. Health Aff 1997:16:239-247.
11. Leon J, Cheng CK, Neumann PJ: Alzheimer's disease care: Costs and potential savings. Health Aff 1998:17:206-216.
12. Leon J, Neumann P: The cost of Alzheimer's disease in managed care: A cross-sectional study. Am J Manag Care 1999;5:867-877.
13. Fillenbaum G, Heyman A, Peterson BL, et al: Use and cost of hospitalization of patients with AD by stage and living arrangement: CERAD XXI. Neurology 2001:56:201-206.
14. Galasko D: An integrated approach to the management of Alzheimer's diseise: Assesing cognition, function and behaviour. Eur J Neurol 1998:5(suppl 4):9-17.
15. Doraiswamy PM, Leon J. Cumming, J. et al: Prevalence and impact of medical comorbidity in Alzheimer's diease. J Gerontol 2002;57A:M173-M177.
16. Rice DP, Fillit HM, Max W. et al: Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective. Am J Manag Care 2001:71:809-818.
17. Fillit H, Gutterman EM, Lewis B: Donepezil use in managed medicare: Effect on health care cost, and utilization. Clin Ther 1999:21:2173-2185.
18. Dello Buono M, Busato R, Mazzetto M, et al: Community care for patients with Alzheimer's disease and non-demented elderly people: Use and satisfaction with services and unmet needs in family caregivers. Int J Geriatr Psychiatry 1999;14:915-924.
19. Gonzalez-Salvador MT, Arango C. Lyketsos CG, et al: The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999;14:701-710.
20. Schulz R, O'Brien AT, Bookwala J, et al: Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995;35:771-791.
21. Ham RJ: Evolving standards in patient and caregiver support. Alzheimer Dis Assoc Disord 1999;13(suppl 2):27-35.
22. Kaufer DI, Sadik K: Galantamine reduces caregiver time spent providing assistance to individuals with mild-to-moderate Alzheimer's disease. Am J Geriatr Psychiatry 2002;10(2 suppl 1):84-85.
23. Feldman H, Gauthier S, Hecker J. et al: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737-744.
24. Small GW, Donohue JA, Brooks RL: An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998;20:838-850.
25. Hill JW, Futterman R, Mastey V, et al: The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface 2002;15(3):63-70.
26. Hauber AB, Gnanasakthy A, Snyder EH, et al: Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 2000;17:351-360.
27. Getsios D, Caro JJ, Caro G, et al: Assessment of Health Economics in Alzheimer's Disease (AHEAD): Galantamine treatment in Canada. Neurology 2001;57:972-978.
28. Knopman D, Schneider L, Davis K, et al: Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996;47:166-177.
29. Lopez OL, Becker JT, Wisniewski S, et al: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-314.
30. Geldmacher DS, Provenzano G, McRae T, et al: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-944.
31. Teri L, Logsdon RG: Assessment and management of behavioral disturbances in Alzheimer disease. Compr Ther 2000;26:169-175.
32. Desai A, Grossberg GT: Recognition and management of behavioral disturbances in dementia. Primary Care Companion to the Journal of Clinical Psychiatry 2001;3:93-109.
33. Burns A, Rossor M, Hecker J, et al: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244.
34. Winblad B, Engedal K, Soininen H, et al: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
35. Raskind MA, Peskind ER, Wessel T, et al: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
36. Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
37. Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-638.
38. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
39. Knopman D, Donohue JA, Gutterman EM: Patterns of care in the early stages of Alzheimer's disease: Impediments to timely diagnosis. J Am Geriatr Soc 2000;48:300-304.
40. Boise L, Camicioli R, Morgan DL, et al: Diagnosing dementia: perspectives of primary care physicians. Gerontologist 1999;39:457-464.
41. Small GW, Rabins PV, Barry PP, et al: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
42. Doody RS, Geldmacher DS, Gordon B, et al: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001;58:427-433.
43. Farlow M, Anand R, Messina Jr J, et al: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-241.
44. Seltzer B, Zolnouni P, Nunez M, et al: Donepezil treatment improves cognitive performance in patients with very mild Alzheimer's disease. Eur Neuropsychopharmacol 2002;12(suppl 3):385.
45. Rogers SL, Doody RS, Pratt RD, et al: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
46. Mohs RC, Doody RS, Morris JC, et al: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488 [erratum in Neurology 2001;57:1942].
47. Mohs RC, Doody RS, Morris JC, et al: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488 [erratum in Neurology 2001;57:1942].
48. Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620 [erratum in: Neurology 2001;57:2153].
49. Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620 [erratum in: Neurology 2001;57:2153].
50. Neumann PJ, Hermann RC, Kunntz KM, et al: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52:1138-1145.
51. Hauber AB, Gnanasakthy A, Mauskopf JA: Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine. Clin Ther 2000;22:439-451.
52. Cummings J, Duttagupta S, Wade S, et al: Cost savings associated with use of donepezil in managed care. Am J Geriatr Psychiatry 2001;9(suppl 1):53.
53. Ernst RL, Hay JW, Fenn C, et al: Cognitive function and the costs of Alzheimer's disease. An exploratory study. Arch Neurol 1997;54:687-693.
54. Wimo A, Winblad B, Engedal K, et al: An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44-54.
55. Sano M, Wilcock GK, Van Baelen B, et al: The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18:942-950.
56. Sano M, Albert SM, Tractenberg R, et al: Developing utilities for stages of Alzheimer's disease using the Clinical Dementia Rating. J Ment Health Aging 1999;5:59-68.
57. O'Brien BJ, Goeree R, Hux M, et al: Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999;47:570-578.
58. Fillit HM, Knopman D, Cummings J, et al: Opportunities for improving managed care for individuals with dementia: Part 2: A framework for care. Am J Manag Care 1999;5:317-324.
59. Fillit HM, Knopman D, Cummings J, et al: Opportunities for improving managed care for individuals with dementia: Part 1: The issues. Am J Manag Care 1999;5:309-315.
60. Fillit HM: Managed care decisions in Alzheimer's disease. Am J Manag Care 2000;6(suppl 22):1149-1160.